Skip to content

This study compares how safe and effective two medicines namely Rupatadine and Fexofenadine are, when taken by mouth to treat allergy.

A comparative study on safety and efficacy of oral fexofenadine and oral rupatadine among patients with allergic rhinitis - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/076733
Enrollment
142
Registered
2024-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: J30- Vasomotor and allergic rhinitis

Interventions

Intervention1: Antihistaminic- rupatadine: tab Rupatadine 10 mg once daily x7 days for each patient enrolled Control Intervention1: Antihistaminic - fexofenadine: tab Fexofenadine 180mg once daily x 7

Sponsors

Rama medical College Hospital and Research CentreKanpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patient of both the sexes in ages 16-60 years of age 2.having one or more features of allergic rhinitis such as sneezing, watery nasal discharge, itching in the nose/throat and nasal blockade. 3.Willing to give Informed & written consent. 4.SNOT score-22 with mild and moderate category

Exclusion criteria

Exclusion criteria: active disease like TB infection Pregnant and lactating women or willing to conceive with known history of hypersensitivity. Patient above age 60 years lean and thin Any chronic diseases like CKD Hepatic diseases

Design outcomes

Primary

MeasureTime frame
Safety and Efficacy of rupatadine and fexofenadine after seven days of treatmentTimepoint: Baseline(Day 0),Day 7,Day14

Secondary

MeasureTime frame
Quality of lifeTimepoint: Baseline(day 0),Day 7,Day 14

Countries

India

Contacts

Public ContactDr Zainab Khatoon

Rama Medical college,kanpur

drkritijalota@gmail.com9450162472

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026